Jove
Visualize
Contact Us

Related Experiment Videos

Proteasomes as drug targets.

Marco Piccinini1, Michael Mostert, Maria Teresa Rinaudo

  • 1Department of Medicine and Experimental Oncology, Section of Biochemistry, University of Turin, Via Michelangelo n 27/B, 10126 Torino Italy.

Current Drug Targets
|October 28, 2003
PubMed
Summary

The ubiquitin-proteasome pathway degrades cellular proteins using the 26S proteasome. Proteasome inhibitors are explored for cancer therapy and treating conditions like ischemia and HIV.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting dihydroorotate dehydrogenase (hDHODH) beyond the barrier: discovery of MEDS700 as blood-brain barrier permeable hDHODH inhibitor.

European journal of medicinal chemistry·2026
Same author

Structure-based design of new pyrazole inhibitors targeting Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH).

European journal of medicinal chemistry·2026
Same author

Fluorescent Isostere (<i>Fluostere</i>) of the Carboxylate: Design of <i>h</i>DHODH Fluorescent Inhibitors as Proof of Concept.

Journal of medicinal chemistry·2025
Same author

Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-<i>a</i>]pyridine Scaffold: SAR of the Aryloxyaryl Moiety.

Journal of medicinal chemistry·2022
Same author

AMPK activation attenuates HER3 upregulation and Neuregulin-Mediated rescue of cell proliferation in HER2-Overexpressing breast cancer cell lines exposed to lapatinib.

Biochemical pharmacology·2022
Same author

Effects of intracellular calcium accumulation on proteins encoded by the major genes underlying amyotrophic lateral sclerosis.

Scientific reports·2022
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Background:

  • The ubiquitin-proteasome pathway (UPP) is crucial for degrading proteins in cytoplasm and nucleus.
  • Protein degradation via UPP involves ubiquitin ligation and ATP, targeting regulatory proteins and damaged molecules.
  • The 26S proteasome is a key ATP-dependent protease central to this pathway.

Purpose of the Study:

  • To review the role of the ubiquitin-proteasome pathway in cellular protein degradation.
  • To discuss the development and applications of proteasome inhibitors.
  • To highlight the therapeutic potential of proteasome inhibitors in various diseases.

Main Methods:

  • Literature review of the ubiquitin-proteasome pathway.
  • Analysis of proteasome inhibitor development and applications.
  • Examination of proteasome inhibitors' roles in cellular processes and disease treatment.

Main Results:

  • Proteasome inhibitors have been developed and used to study UPP functions.
  • Some proteasome inhibitors are in clinical trials for hematologic malignancies, solid tumors, and reperfusion injury.
  • Proteasome inhibitors show potential in interfering with HIV maturation and viral aggressiveness.

Conclusions:

  • The ubiquitin-proteasome pathway is vital for cellular regulation and protein homeostasis.
  • Proteasome inhibitors represent a promising therapeutic strategy for cancer and other diseases.
  • Further research into proteasome inhibitors could lead to novel treatments for viral infections and ischemic conditions.

Related Experiment Videos